Drug Type Small molecule drug |
Synonyms + [3] |
Target |
Mechanism RXRs agonists(Retinoid X receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H32O2 |
InChIKeyBOOOLEGQBVUTKC-NVQSDHBMSA-N |
CAS Registry220619-73-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | - | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | US | 01 May 2016 | |
HER2 Positive Breast Cancer | Phase 1 | US | - | |
Arthritis | Preclinical | US | 15 Aug 2023 | |
Nerve Degeneration | Preclinical | US | 15 Aug 2023 | |
Psoriasis | Preclinical | US | 15 Aug 2023 | |
Alzheimer Disease | Preclinical | US | - | |
Young onset Parkinson disease | Discovery | US | 01 Aug 2014 | |
Castration-Resistant Prostatic Cancer | Discovery | US | 01 Aug 2011 |
Not Applicable | BRCA mutation positive Breast Cancer BRCA1 mutations | - | (bvfkctgzcd) = vzxikdzyfi evuvqzwusk (wbaoccrajl ) | Positive | 15 Oct 2021 | ||
IRX-4204 10mg/kg | (bvfkctgzcd) = pntezxwmmf evuvqzwusk (wbaoccrajl ) | ||||||
Phase 2 | 38 | avjgtqwfaj(wtcltsfcbf) = bcjgexhhgo uvdlqdqtfs (oufitsefek, mgjeqndknc - eepppmsvhw) View more | - | 14 May 2021 | |||
Phase 2 | 23 | (tgjwghdlva) = biqeczxxxv ajgyhwsccd (eivycjecno ) | Positive | 20 May 2014 |